MODERNA INC

Moderna shares soar 12% after breakthrough Phase 3 results for its mRNA melanoma therapy, intismeran autogene, heading to a pivotal ESMO Congress reveal.

Explore Moderna’s latest FDA‑approved mRNA flu vaccine, breakthrough melanoma trials, and market trends—discover how this biotech firm’s expanding pipeline could reshape investors’ outlook.

Moderna’s Phase‑III melanoma vaccine shows 23% overall survival boost, sparking a 179% share surge and marking a pivotal shift toward mRNA oncology.

Moderna’s stock soars 170% after breakthrough melanoma mRNA vaccine results, then pulls back as analysts weigh valuation risks and future potential.

Moderna stock surges 160% after breakthrough melanoma vaccine data, sparking analyst upgrades and $4.8 billion short‑seller losses.

Moderna’s U.S. mRNA flu vaccine approval boosts shares, showing investor confidence in its expanding vaccine portfolio and mRNA tech.

Moderna’s mRNA breakthrough fuels biotech buzz—stock hits $80, 31 billion cap, and FDA wins boost investor interest amid Fed‑rate hopes.

Moderna’s stock surged 9.2% on July 2 2026 after strong flu vaccine data, pipeline updates, and bullish analyst sentiment—boosting the healthcare sector and driving mRNA investment interest.

Moderna’s steady rise to $72.50 shows 131% gains from last year, driven by a strong mRNA pipeline and solid biotech market momentum.

Moderna’s breakthrough mRNA flu vaccine and hantavirus research boost share price, analyst upgrades, and market optimism for the biotech firm.